<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082003</url>
  </required_header>
  <id_info>
    <org_study_id>LHS T-E01</org_study_id>
    <nct_id>NCT01082003</nct_id>
  </id_info>
  <brief_title>Prevention of Capsular Contracture Using Trental and Vitamin E</brief_title>
  <official_title>A Single Center, Prospective Treatment Trial to Assess Prophylactic Use of Trental (Pentoxifylline) and Vitamin E to Prevent Capsular Contracture After Implant Reconstruction in Patients Requiring Adjuvant Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Legacy Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research study is to determine if the use of Trental and Vitamin E&#xD;
      will decrease the incidence and severity of contractures (shrinking and or hardening of&#xD;
      tissue surrounding the implant) associated with breast implant reconstruction following&#xD;
      radiation treatment. Another goal is to find out the impact that Trental and Vitamin E have&#xD;
      on implant loss or need for surgical intervention in the setting of chest wall radiation&#xD;
      after reconstruction. In addition, the investigators want to evaluate the patient's sense of&#xD;
      well being and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, 18-month study in which 30 women will receive Trental&#xD;
      (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400&#xD;
      international units orally twice daily for six months. Subjects will begin the treatment&#xD;
      regimen within four weeks after completion of radiation treatment and will remain on the&#xD;
      study drugs for six months. Following completion of active treatment, all subjects will enter&#xD;
      the twelve-month observational phase of the trial in which they will be evaluated for changes&#xD;
      in breast tissue using the following objective tools: Bakers Grade Assessment, Visual Analog&#xD;
      Scale (VAS), implant revision or loss, breast photographs, adverse event assessment and the&#xD;
      Quality of Life tool (SF-12).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure number and grade of contractures occurring after implant reconstruction and radiation treatment in subjects receiving Trental and vitamin E combination compared to placebo using the Bakers grade assessment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of implant revisions or loss of implants due to post radiation changes in subject receiving Trental and vitamin E compared to placebo through patient interview with research staff</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Capsular Contractures</condition>
  <arm_group>
    <arm_group_label>Permanent Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trental and Vitamin E for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tissue Expander</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trental and Vitamin E for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trental</intervention_name>
    <description>Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.</description>
    <arm_group_label>Permanent Implant</arm_group_label>
    <arm_group_label>Tissue Expander</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Expected survival at least &gt; 6 months&#xD;
&#xD;
          -  Undergone mastectomy with expander or implant reconstruction &gt; 3 weeks before&#xD;
             radiation therapy&#xD;
&#xD;
          -  Completed chest wall irradiation in the past two weeks&#xD;
&#xD;
          -  Willing to stop herbal medications as directed by physician&#xD;
&#xD;
          -  Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E&#xD;
             component is acceptable)&#xD;
&#xD;
          -  Willing to travel to a Legacy Health System facility&#xD;
&#xD;
          -  Agree to attend study visits outside of standard of care visits&#xD;
&#xD;
          -  Normal PT-INR for subjects taking Coumadin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Have final implant placed &lt; 3 weeks before start of radiation therapy&#xD;
&#xD;
          -  Have evidence of ongoing infection or implant exposure before start of radiation&#xD;
             therapy&#xD;
&#xD;
          -  Radiation completed more than 16 days prior to study start&#xD;
&#xD;
          -  Retinitis Pigmentosa&#xD;
&#xD;
          -  Unable to comply with protocol&#xD;
&#xD;
          -  Unable to provide written informed consent&#xD;
&#xD;
          -  Unwilling or unable to stop supplemental vitamin E&#xD;
&#xD;
          -  PT-INR outside of acceptable range for subjects taking Coumadin&#xD;
&#xD;
          -  Investigator does not believe study participation, for any reason is in the best&#xD;
             interest of the patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Legacy Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Legacy Good Samaritan Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Legacy Health System</investigator_affiliation>
    <investigator_full_name>Nathalie Johnson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Capsular contractures in breast cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

